Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma


Disclosures: J.H., M.K., J.M., K.D., and M.L. are or have been employees of Kyowa Kirin; A.A.P has received research funding from Kyowa Kirin, and financial compensation for providing advisory/consulting roles to Kyowa Kirin, Celgene, and Genentech; S.M.H. has received research funding from Kyowa Kirin, Celgene, Millenium/Takeda, Seattle Genetics, Forty-Seven, BMS, Infinity/Verastem, ADCT Therapeutics and Aileron Therapeutics, financial compensation as honoraria or for providing advisory/consulting roles to Kyowa Kirin, Celgene, Millenium/Takeda, Seattle Genetics, Forty-Seven, BMS, and Mundipharma, and reimbursement of travel/accommodation/expenses from Kyowa Kirin; L.C. has received financial compensation for providing advisory/consulting roles to Kyowa Kirin and Innate Pharma, honoraria from Roche, and speakers bureau fees from Gilead; T.F. has received financial compensation for travel/accommodation/expenses from Kyowa Kirin, and honoraria for consultancy/speakers bureau from Seattle Genetics, Takeda, BMS, Pharmacyclics/Jannsen, AbbVie, Celgene, and Kite Pharma; F.W. has received financial compensation as an educational grant from Gilead, financial compensation for providing an advisory/consulting role to Pfizer, speakers bureau fees from BMS, Roche, and Boehringer, and reimbursement of travel/accommodation/expenses from Celgene and Gilead; G.P.T. has received research funding from Kyowa Kirin; J.P. has received speakers bureau fees from Roche and Genentech, and has received financial compensation for providing an advisory/consulting role to Libbs; J.C.R. has received honoraria from Cardinal Health, financial compensation for providing advisory/consulting roles to Cardinal Health, and reimbursement travel/accommodation/expenses from Cardinal Health and miRagen Therapeutics; AS has received financial compensation for providing advisory/consulting roles to Kyowa Kirin; the remaining author (K.C.) declares no competing financial interests.